These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 19369462

  • 1. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.
    Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH.
    J Rheumatol; 2009 Jul; 36(7):1429-41. PubMed ID: 19369462
    [Abstract] [Full Text] [Related]

  • 2. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE, ATTRACT Study Group.
    Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
    [Abstract] [Full Text] [Related]

  • 3. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER.
    van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewé R, Patra K, Pangan AL.
    J Rheumatol; 2010 Nov; 37(11):2237-46. PubMed ID: 20889601
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.
    Keystone EC, Haraoui B, Guérette B, Mozaffarian N, Liu S, Kavanaugh A.
    J Rheumatol; 2014 Feb; 41(2):235-43. PubMed ID: 24293583
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study.
    Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, Santra S, Smolen JS.
    Ann Rheum Dis; 2013 Jan; 72(1):64-71. PubMed ID: 22562973
    [Abstract] [Full Text] [Related]

  • 9. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
    Huang F, Zhang FC, Bao CD, Tao Y, Gu JR, Xu JH, Zhu P, Xu HJ, Zhang ZY, Zhao DB, Wu DH.
    Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
    [Abstract] [Full Text] [Related]

  • 10. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
    Detert J, Bastian H, Listing J, Weiß A, Wassenberg S, Liebhaber A, Rockwitz K, Alten R, Krüger K, Rau R, Simon C, Gremmelsbacher E, Braun T, Marsmann B, Höhne-Zimmer V, Egerer K, Buttgereit F, Burmester GR.
    Ann Rheum Dis; 2013 Jun; 72(6):844-50. PubMed ID: 22739990
    [Abstract] [Full Text] [Related]

  • 11. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis.
    Keystone EC, van der Heijde D, Kavanaugh A, Kupper H, Liu S, Guérette B, Mozaffarian N.
    J Rheumatol; 2013 Sep; 40(9):1487-97. PubMed ID: 23818718
    [Abstract] [Full Text] [Related]

  • 12. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.
    Yamanaka H, Ishiguro N, Takeuchi T, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Kupper H, Arora V, Tanaka Y.
    Rheumatology (Oxford); 2014 May; 53(5):904-13. PubMed ID: 24441150
    [Abstract] [Full Text] [Related]

  • 13. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V, Rentz AM, Cifaldi MA, Chen N, Roy S, Revicki D.
    J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
    [Abstract] [Full Text] [Related]

  • 14. Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis.
    Keystone EC, Kavanaugh A, Weinblatt ME, Patra K, Pangan AL.
    J Rheumatol; 2011 May; 38(5):855-62. PubMed ID: 21285171
    [Abstract] [Full Text] [Related]

  • 15. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.
    O'Dell JR, Curtis JR, Mikuls TR, Cofield SS, Bridges SL, Ranganath VK, Moreland LW, TEAR Trial Investigators.
    Arthritis Rheum; 2013 Aug; 65(8):1985-94. PubMed ID: 23686414
    [Abstract] [Full Text] [Related]

  • 16. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis.
    Chen DY, Chou SJ, Hsieh TY, Chen YH, Chen HH, Hsieh CW, Lan JL.
    J Formos Med Assoc; 2009 Apr; 108(4):310-9. PubMed ID: 19369178
    [Abstract] [Full Text] [Related]

  • 17. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [Abstract] [Full Text] [Related]

  • 18. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.
    Keystone EC, Breedveld FC, van der Heijde D, Landewé R, Florentinus S, Arulmani U, Liu S, Kupper H, Kavanaugh A.
    J Rheumatol; 2014 Jan; 41(1):5-14. PubMed ID: 24241487
    [Abstract] [Full Text] [Related]

  • 19. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
    Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, Bridges SL, Zhang J, McVie T, Howard G, van der Heijde D, Cofield SS, TEAR Investigators.
    Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468
    [Abstract] [Full Text] [Related]

  • 20. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.
    Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, Guérette B, Kupper H, Redden L, Arora V, Kavanaugh A.
    Lancet; 2014 Jan 25; 383(9914):321-32. PubMed ID: 24168956
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.